Interdigitating Dendritic Cell Sarcoma

Gaertner, Erich M.; Tsokos, Maria; Derringer, Gregory A.; Neuhauser, Thomas S.; Arciero, Cletus A.; Andriko, Jo‐Ann W.

doi:10.1309/m95g-7dq2-tlql-7q11

Cited by 121 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histiocytic/dendritic cell sarcomas are rare neoplasms which typically originate from low-grade lymphomas [4][5][6][7][8]. In a recent report of eight cases [11], there were five men and three women, age ranging from 30 to 70 years (median 59 years).…”

Section: Discussionmentioning

confidence: 99%

Histiocytic/dendritic cell sarcoma arising from follicular lymphoma involving the bone: a case report and review of literature

et al. 2009

View full text Add to dashboard Cite

Histiocytic/dendritic cell sarcomas arising from follicular lymphoma are very rare and poorly understood lesions. We describe a case, which is unique in that it presented with a hipbone lesion simultaneously with axillary lymphadenopathy. Biopsy of the axillary lymph node showed a low-grade follicular lymphoma. The hipbone lesion was comprised two cell populations, one representing diffuse large B cell lymphoma and the other a histiocytic/dendritic sarcoma. The cells of all three lesions contained an IGH/BCL2 rearrangement, suggesting that both diffuse large B cell lymphoma and histiocytic/dendritic sarcoma differentiation developed from the same low grade precursor (follicular lymphoma). This case illustrates that sarcomatous transdifferentiation of follicular lymphoma can be an unpredictable local phenomenon and that it can occur extra nodally in the bone marrow. It may also occur concurrently with the progression of follicular lymphoma to a diffuse large B cell lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Histiocytic/dendritic cell sarcoma arising from follicular lymphoma involving the bone: a case report and review of literature

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Interdigitating dendritic cells are an antigen presenting cells observed on T cells of the peripheral lymphoid tissues, and sarcoma originating on it is very rare and is histologically similar with B cell lymphoma or T cell lymphoma and other spindle cell neoplasm [2]. …”

Section: Discussionmentioning

confidence: 99%

“…Most IDCS occurs in the lymph node (particularly in the collum, the mediastinum and axilla) and around one third of it is found in other organs except the lymph node. For the organs, the liver is observed most frequently, while others are the spleen, the skin, the lung, the rhinopharynx, the small intestine and the breast [1,2]. …”

Section: Introductionmentioning

confidence: 99%

Interdigitating dendritic cell sarcoma occured alone in axilla

Han

Kim

et al. 2012

J Korean Surg Soc

View full text Add to dashboard Cite

Interdigitating dendritic cell sarcoma (IDCS) is a very rare disease around the world and its prognosis is known to be aggressive. This reports a case diagnosed as IDCS of the axillary region treated in Soonchunhyang University Hospital. A 57-year-old female visited Soonchunhyang University Hospital with a left axillary mass. The mass was hard and fixed. Computed tomography observed a 7 cm lymph node at the left axilla, and core biopsy suspected sarcoma. In another study, there was no specific finding except the axillary lesion. Left axillary lymph node dissection (level I, II) was conducted and the pathologic report finally showed IDCS. The patient was treated with only radiotherapy and followed up without recurrence for 13 months up to now. IDCS is a very rare sarcoma that is hard to diagnose and progresses fast. Thus, treatment is very difficult. Proper treatment can be better established after more experiences.

show abstract

“…IDCS is a very rare disease, with a challenging diagnosis. Under electron microscope, there were no signs of Birbeck granules 3, 4 . The clinical guidelines including the histopathology, prognostic factors and treatment protocol, have not yet confirmed.…”

Section: Introductionmentioning

confidence: 90%

“…The clinical guidelines including the histopathology, prognostic factors and treatment protocol, have not yet confirmed. IDCS cases had a variation in prognosis: some cases had good outcomes, some cases worsened and even died, and some cases experienced another hematopoietic or solid organ malignancy 3, 5–14 . As to the heterogeneous clinical features, this study aimed to make two cases report and a pooled analysis of reported cases in order to clarify prognostic potency in histopathological factors and provide the practical reference of oncologist and pathologist.…”

Section: Introductionmentioning

confidence: 99%

Diffuse lesion and necrosis tied to poorer prognosis of interdigitating dendritic cell sarcoma: cases report and a pooled analysis

Shi

Song

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Interdigitating dendritic cell sarcoma is a neoplastic proliferation of interdigitating dendritic cells and no therapeutic consensus exists. This study aimed to investigate the prognostic impacts of tumor lesion, cellular atypia, mitosis and necrosis on the interdigitating dendritic cell sarcoma. Case reports and pooled analyses were designed to explore the relationships. One case was a 40-years old man with localized lesion, moderate to notable cellular atypia, 30 mitoses per 10 high-power fields and no necrosis and the progression-free survival was longer than 20 months. The other case was a 62-years old woman with diffuse lesion, notable cellular atypia, less than one mitosis per 10 high-power fields and diffuse necrosis and the progression-free survival was shorter than 1 month. Cellular atypia and mitosis had not any relationship with survival. Compared with localized lesion, diffuse lesion presented a 2.92-fold risk of progression (HR = 2.92, 95% CI 1.01, 8.51) and an 8.79-fold risk of death (HR = 8.79, 95% CI 1.86, 41.64). Diffuse necrosis presented a 4.39-fold higher progression risk (HR = 5.39, 95% CI 1.78, 16.29) and a 5.37-fold higher death risk (HR = 6.37, 95% CI 1.46, 27.86) than focal or no necrosis. Diffuse lesion and diffuse necrosis were indicators of poorer prognosis and the clinical application should be warranted in further studies.

show abstract

Interdigitating Dendritic Cell Sarcoma

Cited by 121 publications

References 29 publications

Histiocytic/dendritic cell sarcoma arising from follicular lymphoma involving the bone: a case report and review of literature

Histiocytic/dendritic cell sarcoma arising from follicular lymphoma involving the bone: a case report and review of literature

Interdigitating dendritic cell sarcoma occured alone in axilla

Diffuse lesion and necrosis tied to poorer prognosis of interdigitating dendritic cell sarcoma: cases report and a pooled analysis

Contact Info

Product

Resources

About